Published in FASEB J on April 01, 2004
Intravenous erythropoietin in patients with ST-segment elevation myocardial infarction: REVEAL: a randomized controlled trial. JAMA (2011) 4.09
Pathogenesis of myocardial ischemia-reperfusion injury and rationale for therapy. Am J Cardiol (2010) 2.52
Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC Med Genomics (2009) 2.36
Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol (2009) 1.59
Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med (2008) 1.36
Erythropoietin involves the phosphatidylinositol 3-kinase pathway, 14-3-3 protein and FOXO3a nuclear trafficking to preserve endothelial cell integrity. Br J Pharmacol (2007) 1.33
The erythropoietin receptor is a downstream effector of Klotho-induced cytoprotection. Kidney Int (2013) 1.27
Sonic hedgehog is a critical mediator of erythropoietin-induced cardiac protection in mice. J Clin Invest (2010) 1.06
Erythropoietin in the intensive care unit: beyond treatment of anemia. Ann Intensive Care (2011) 1.03
Effects of erythropoietin on the bone microenvironment. Growth Factors (2011) 1.00
Design and rationale of the Reduction of Infarct Expansion and Ventricular Remodeling with Erythropoietin after Large Myocardial Infarction (REVEAL) trial. Am Heart J (2010) 1.00
Simultaneous administration of insulin-like growth factor-1 and darbepoetin alfa protects the rat myocardium against myocardial infarction and enhances angiogenesis. Clin Transl Sci (2008) 1.00
Erythropoietin receptor contributes to melanoma cell survival in vivo. Oncogene (2011) 0.96
p42/p44-MAPK and PI3K are sufficient for IL-6 family cytokines/gp130 to signal to hypertrophy and survival in cardiomyocytes in the absence of JAK/STAT activation. Cell Signal (2012) 0.96
Use of high-dose erythropoietin for repair after injury: A comparison of outcomes in heart and kidney. J Nephropathol (2013) 0.96
Erythropoietin, a novel versatile player regulating energy metabolism beyond the erythroid system. Int J Biol Sci (2014) 0.96
Promises and pitfalls in erythopoietin-mediated tissue protection: are nonerythropoietic derivatives a way forward? J Investig Med (2011) 0.92
Erythropoietin expands a stromal cell population that can mediate renoprotection. Am J Physiol Renal Physiol (2008) 0.91
Erythropoietin protects the human myocardium against hypoxia/reoxygenation injury via phosphatidylinositol-3 kinase and ERK1/2 activation. Br J Pharmacol (2007) 0.90
The role of erythropoietin as an inhibitor of tissue ischemia. Int J Biol Sci (2008) 0.89
Acute erythropoietin cardioprotection is mediated by endothelial response. Basic Res Cardiol (2011) 0.88
EPO promotes bone repair through enhanced cartilaginous callus formation and angiogenesis. PLoS One (2014) 0.88
Cardiorenal Syndrome and the Role of the Bone-Mineral Axis and Anemia. Am J Kidney Dis (2015) 0.87
Evaluation of functional erythropoietin receptor status in skeletal muscle in vivo: acute and prolonged studies in healthy human subjects. PLoS One (2012) 0.85
Protecting mitochondrial bioenergetic function during resuscitation from cardiac arrest. Crit Care Clin (2012) 0.85
Pyruvate-fortified cardioplegia evokes myocardial erythropoietin signaling in swine undergoing cardiopulmonary bypass. Am J Physiol Heart Circ Physiol (2009) 0.85
Clinical significance of erythropoietin receptor expression in oral squamous cell carcinoma. BMC Cancer (2012) 0.85
Left ventricular functional assessment in murine models of ischemic and dilated cardiomyopathy using [18 F]FDG-PET: comparison with cardiac MRI and monitoring erythropoietin therapy. EJNMMI Res (2012) 0.85
Novel adjunctive treatments of myocardial infarction. World J Cardiol (2014) 0.84
Erythropoietin protects cardiac myocytes against anthracycline-induced apoptosis. Biochem Biophys Res Commun (2007) 0.82
Gata4 and Sp1 regulate expression of the erythropoietin receptor in cardiomyocytes. J Cell Mol Med (2011) 0.82
A novel EPO receptor agonist improves glucose tolerance via glucose uptake in skeletal muscle in a mouse model of diabetes. Exp Diabetes Res (2011) 0.82
EPC mobilization after erythropoietin treatment in acute ST-elevation myocardial infarction: the REVEAL EPC substudy. J Thromb Thrombolysis (2013) 0.81
Early sustained injections of erythropoietin improve angiogenesis and restoration of perfusion in the ischemic mouse hindlimb. J Korean Med Sci (2012) 0.81
Pharmacological postconditioning effect of muramyl dipeptide is mediated through RIP2 and TAK1. Cardiovasc Res (2009) 0.80
Anemia correction by erythropoietin reduces BNP levels, hospitalization rate, and NYHA class in patients with cardio-renal anemia syndrome. Clin Exp Med (2010) 0.80
The influence of Erythropoietin on platelet activation, thrombin generation and FVII/active FVII in patients with AMI. Thromb J (2014) 0.80
Prognostic significance of left ventricular hypertrophy observed at dialysis initiation depends on the pre-dialysis use of erythropoiesis-stimulating agents. Clin Exp Nephrol (2012) 0.79
Cardiovascular effects of erythropoietin an update. Adv Pharmacol (2010) 0.79
Fabrication of Murine Ventricular Balloons for the Langendorff Heart Preparation. J Biotechnol Biomater (2011) 0.78
Antioxidant and antiapoptotic effects of darbepoetin-α against traumatic brain injury in rats. Arch Med Sci (2015) 0.77
Erythropoietin prevents endothelial dysfunction in GTP-cyclohydrolase I-deficient hph1 mice. J Cardiovasc Pharmacol (2014) 0.77
Erythropoietin-driven signalling and cell migration mediated by polyADP-ribosylation. Br J Cancer (2012) 0.76
The effect of erythropoietin on biomechanical properties of the Achilles tendon during the healing process: an experimental study. J Orthop Surg Res (2016) 0.75
Mechanism of cardioprotective effect of erythropoietin-induced preconditioning in rat heart. Indian J Pharmacol (2010) 0.75
Effect of Erythropoietin in patients with acute myocardial infarction: five-year results of the REVIVAL-3 trial. BMC Cardiovasc Disord (2017) 0.75
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med (2012) 9.69
Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev (2008) 5.52
5'-AMP-activated protein kinase (AMPK) is induced by low-oxygen and glucose deprivation conditions found in solid-tumor microenvironments. Mol Cell Biol (2006) 4.28
Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation (2009) 3.45
The physiological role of mitochondrial calcium revealed by mice lacking the mitochondrial calcium uniporter. Nat Cell Biol (2013) 3.39
Three techniques for integrating data in mixed methods studies. BMJ (2010) 3.19
Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATP-sensitive K+ channels and p42/p44 MAPK pathway. Circ Res (2004) 2.98
Preconditioning results in S-nitrosylation of proteins involved in regulation of mitochondrial energetics and calcium transport. Circ Res (2007) 2.97
Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes. Circ Res (2004) 2.91
Deoxymyoglobin is a nitrite reductase that generates nitric oxide and regulates mitochondrial respiration. Circ Res (2007) 2.91
Hypercontractile female hearts exhibit increased S-nitrosylation of the L-type Ca2+ channel alpha1 subunit and reduced ischemia/reperfusion injury. Circ Res (2006) 2.84
Phosphorylation of glycogen synthase kinase-3beta during preconditioning through a phosphatidylinositol-3-kinase--dependent pathway is cardioprotective. Circ Res (2002) 2.50
Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function. Circ Res (2006) 2.33
Targeted deletion of thioredoxin-interacting protein regulates cardiac dysfunction in response to pressure overload. Circ Res (2007) 2.31
Autologous mesenchymal stem cells produce reverse remodelling in chronic ischaemic cardiomyopathy. Eur Heart J (2009) 2.29
American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol (2010) 2.16
Intramyocardial injection of autologous cardiospheres or cardiosphere-derived cells preserves function and minimizes adverse ventricular remodeling in pigs with heart failure post-myocardial infarction. J Am Coll Cardiol (2011) 2.15
Cyclophilin D controls mitochondrial pore-dependent Ca(2+) exchange, metabolic flexibility, and propensity for heart failure in mice. J Clin Invest (2010) 2.12
The nuclear receptor ERRalpha is required for the bioenergetic and functional adaptation to cardiac pressure overload. Cell Metab (2007) 2.11
Vitamin D deficiency in multicultural primary care: a case series of 299 patients. Br J Gen Pract (2007) 2.02
Nuclear miRNA regulates the mitochondrial genome in the heart. Circ Res (2012) 1.95
Preconditioning: the mitochondrial connection. Annu Rev Physiol (2007) 1.93
Why, and how, mixed methods research is undertaken in health services research in England: a mixed methods study. BMC Health Serv Res (2007) 1.91
Controlled activation of morphogenesis to generate a functional human microvasculature in a synthetic matrix. Blood (2011) 1.91
Inhibition of delta-protein kinase C protects against reperfusion injury of the ischemic heart in vivo. Circulation (2003) 1.80
The quality of mixed methods studies in health services research. J Health Serv Res Policy (2008) 1.75
Mitochondrial dysfunction and apoptosis underlie the pathogenic process in alpha-B-crystallin desmin-related cardiomyopathy. Circulation (2005) 1.72
Transgenic expression of Bcl-2 modulates energy metabolism, prevents cytosolic acidification during ischemia, and reduces ischemia/reperfusion injury. Circ Res (2004) 1.69
Qualitative study investigating the process of giving anti-smoking advice in general practice. Patient Educ Couns (2004) 1.67
Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica (2013) 1.67
New horizons in cardioprotection: recommendations from the 2010 National Heart, Lung, and Blood Institute Workshop. Circulation (2011) 1.66
Protein S-nitrosylation and cardioprotection. Circ Res (2010) 1.63
Essential role of nitric oxide in acute ischemic preconditioning: S-nitros(yl)ation versus sGC/cGMP/PKG signaling? Free Radic Biol Med (2012) 1.61
A practical guide for clinicians who treat patients with amiodarone: 2007. Heart Rhythm (2007) 1.61
Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res (2008) 1.60
Activation of a novel estrogen receptor, GPER, is cardioprotective in male and female rats. Am J Physiol Heart Circ Physiol (2009) 1.59
SU5416 delays wound healing through inhibition of TGF-beta 1 activation. Cancer Biol Ther (2002) 1.58
Gender-based differences in mechanisms of protection in myocardial ischemia-reperfusion injury. Cardiovasc Res (2007) 1.57
Ethnic differences in self-harm, rates, characteristics and service provision: three-city cohort study. Br J Psychiatry (2010) 1.57
Estrogen receptor-beta activation results in S-nitrosylation of proteins involved in cardioprotection. Circulation (2009) 1.56
Cyclophilin D modulates mitochondrial acetylome. Circ Res (2013) 1.53
Simultaneous measurement of protein oxidation and S-nitrosylation during preconditioning and ischemia/reperfusion injury with resin-assisted capture. Circ Res (2010) 1.48
Erythropoietin biology in cancer. Clin Cancer Res (2006) 1.48
Estrogen receptor beta mediates gender differences in ischemia/reperfusion injury. J Mol Cell Cardiol (2005) 1.47
Retracted The NAD-dependent deacetylase SIRT2 is required for programmed necrosis. Nature (2012) 1.44
S-nitrosylation: NO-related redox signaling to protect against oxidative stress. Antioxid Redox Signal (2006) 1.43
Failure of terminal erythroid differentiation in EKLF-deficient mice is associated with cell cycle perturbation and reduced expression of E2F2. Mol Cell Biol (2008) 1.42
Estrogen receptor-beta mediates male-female differences in the development of pressure overload hypertrophy. Am J Physiol Heart Circ Physiol (2004) 1.41
Adenoviral transfer of HIF-1alpha enhances vascular responses to critical limb ischemia in diabetic mice. Proc Natl Acad Sci U S A (2009) 1.41
Detection of left ventricular thrombus by delayed-enhancement cardiovascular magnetic resonance prevalence and markers in patients with systolic dysfunction. J Am Coll Cardiol (2008) 1.41
Advancing geriatrics education: an efficient faculty development program for academic hospitalists increases geriatric teaching. J Hosp Med (2010) 1.40
The 5-tier system of assessing fetal heart rate tracings is superior to the 3-tier system in identifying fetal acidemia. Am J Obstet Gynecol (2011) 1.40
Sex differences in the phosphorylation of mitochondrial proteins result in reduced production of reactive oxygen species and cardioprotection in females. Circ Res (2010) 1.40
Characterization of potential S-nitrosylation sites in the myocardium. Am J Physiol Heart Circ Physiol (2011) 1.37
Nurse and pharmacist supplementary prescribing in the UK--a thematic review of the literature. Health Policy (2007) 1.33
Cardiac-specific ablation of the Na+-Ca2+ exchanger confers protection against ischemia/reperfusion injury. Circ Res (2005) 1.32
G protein-coupled receptor internalization signaling is required for cardioprotection in ischemic preconditioning. Circ Res (2004) 1.27
Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J (2005) 1.27
A novel role for erythropoietin during fibrin-induced wound-healing response. Am J Pathol (2003) 1.26
Creatine kinase-mediated improvement of function in failing mouse hearts provides causal evidence the failing heart is energy starved. J Clin Invest (2011) 1.26
Detection of human CYP2C8, CYP2C9, and CYP2J2 in cardiovascular tissues. Drug Metab Dispos (2007) 1.25
2011 consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovasc Pathol (2011) 1.24
Dextran hydrogel scaffolds enhance angiogenic responses and promote complete skin regeneration during burn wound healing. Proc Natl Acad Sci U S A (2011) 1.24
Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest (2002) 1.23
Regulation of myocyte contraction via neuronal nitric oxide synthase: role of ryanodine receptor S-nitrosylation. J Physiol (2010) 1.22
Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One (2007) 1.19
Multidisciplinary, interdisciplinary, or dysfunctional? Team working in mixed-methods research. Qual Health Res (2008) 1.19
Treatment with an estrogen receptor-beta-selective agonist is cardioprotective. J Mol Cell Cardiol (2007) 1.19
Cysteine 203 of cyclophilin D is critical for cyclophilin D activation of the mitochondrial permeability transition pore. J Biol Chem (2011) 1.18
Skeletal muscle ATP kinetics are impaired in frail mice. Age (Dordr) (2013) 1.18
S-nitrosylation: a radical way to protect the heart. J Mol Cell Cardiol (2011) 1.16
Stakeholders' views of UK nurse and pharmacist supplementary prescribing. J Health Serv Res Policy (2008) 1.14
The role of beta-adrenergic receptor signaling in cardioprotection. FASEB J (2005) 1.13
Ablation of PLB exacerbates ischemic injury to a lesser extent in female than male mice: protective role of NO. Am J Physiol Heart Circ Physiol (2002) 1.13